A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER

  • Authors:
    • HL PARNES
    • N TAIT
    • B CONLEY
    • D VANECHO
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/or.2.6.1131
  • Pages: 1131-1134
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

CPT-11 is a topoisomerase I inhibitor with activity against colorectal cancer. This study was designed to explore the potential for combining CPT-11 with fluorouracil and leucovorin. 5-FU (500 mg/m(2)) and leucovorin (500 mg/m(2)) were administered for 4 consecutive weeks and CPT-11 was given on weeks 1 and 4 of each 6 week cycle. The starting dose of CPT-11 was 25 mg/m(2) and the dosage was escalated by increments of 25 mg/m(2) in cohorts of 3 patients. Nine patients were treated on study. Grade 4 diarrhea was the dose limiting toxicity at 50 mg/m(2). Alternative strategies to combine CPT-11 with 5-FU and leucovorin are being explored.

Related Articles

Journal Cover

November 1995
Volume 2 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
PARNES H, TAIT N, CONLEY B and VANECHO D: A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER. Oncol Rep 2: 1131-1134, 1995
APA
PARNES, H., TAIT, N., CONLEY, B., & VANECHO, D. (1995). A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER. Oncology Reports, 2, 1131-1134. https://doi.org/10.3892/or.2.6.1131
MLA
PARNES, H., TAIT, N., CONLEY, B., VANECHO, D."A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER". Oncology Reports 2.6 (1995): 1131-1134.
Chicago
PARNES, H., TAIT, N., CONLEY, B., VANECHO, D."A PHASE-I STUDY OF CPT-11, WEEKLY BOLUS 5-FU AND LEUCOVORIN IN PATIENTS WITH METASTATIC CANCER". Oncology Reports 2, no. 6 (1995): 1131-1134. https://doi.org/10.3892/or.2.6.1131